Proprietary Adjuvant System Induces Improved Immune Response vs. Conventional Formulation


GlaxoSmithKline’s (GSK) candidate vaccine for the prevention of cervical cancer formulated with proprietary AS04 adjuvant system claims to have better immune response compared with the vaccine formulated with conventional aluminum salt adjuvant.

Sign in below or register now to access this 3-page PDF white paper.

Author: GlaxoSmithKline  | File Type: PDF

Find more white papers on Industry Developments

View all white papers»